Herantis Pharma Oyj (HRTIS) Earnings Call Transcripts

Herantis Pharma Oyj's Latest Earnings Call - June 2, 2026

In the Q2 2026 earnings call, Herantis Pharma Oyj (HRTIS:FI) provided a comprehensive update on the Phase II clinical trial plans for HER-096, a disease-modifying therapy for Parkinson's disease. The company reported that it has secured over 50% of the required funding for the trial, including an EU Horizon grant of EUR 8 million. Management highlighted positive FDA feedback on the trial design, stating, "the agency was very interested in our approach, applauded the approach," which could enhance investor confidence moving forward. No revenue or earnings figures were disclosed, as the company remains in the clinical stage with no commercial product yet available.

Reported metrics

Guidance from management

Management expects to submit the clinical trial application by the end of 2026 and anticipates enrolling the first patient in the first half of 2027, with efficacy data readout expected in early 2029.

What management said

So for a participant, this would mean a smartphone-based continuous assessment. Can you tell us a little bit more on how the digital motor score, how -- what are the different types of tests, the composite, how it's built? What does the digital motor score mean in practice?

So where would you say that the digital health technologies in general are? They still -- there are not many endpoint, digital endpoints that have a regulatory acceptance or approval. Are there examples of clinical trials, for example, in Parkinson's where digital motor score has been incorporated in the study design?

What analysts pressed on

Analysts expressed concerns regarding the regulatory acceptance of digital endpoints and the potential challenges in demonstrating the efficacy of HER-096 compared to traditional treatments. There is also apprehension about securing the remaining funding required for the trial and the timeline for achieving pivotal trial data.

Main topics on the call

• Phase II Clinical Trial Plans — Herantis plans to conduct a proof-of-concept Phase IIa trial enrolling approximately 100 de novo Parkinson's patients. The trial will feature a randomized placebo-controlled design lasting 6 months, followed by a 6-month...
• FDA Feedback — Management reported positive feedback from a pre-IND meeting with the FDA, stating, "the agency was very interested in our approach, applauded the approach." This endorsement could facilitate smoother regulatory interact...
• Funding Status — Herantis has secured over 50% of the funding needed for the Phase II trial, including an EUR 8 million grant from the EU Horizon program. Management emphasized the importance of timely trial initiation to maximize shareh...
• Collaboration with Indivi — The partnership with Indivi aims to leverage digital health technologies for objective assessment of motor symptoms in Parkinson's trials. This collaboration is expected to enhance the sensitivity of outcome measures, po...

Read the full Herantis Pharma Oyj transcript (June 2, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 20 Herantis Pharma Oyj earnings call transcripts on record, spanning February 28, 2020 to June 2, 2026. Based on this history, Herantis Pharma Oyj reports semi-annually. The most recent call on file is dated June 2, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

HRTIS

Exchange

HLSE

Country

FI

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

20

First call

February 28, 2020

Most recent

June 2, 2026

Reporting cadence

semi-annually